Diamedica Therapeutics Inc Stock Price, News & Analysis

DiaMedica Therapeutics (Nasdaq: DMAC) reported third quarter 2025 results and a business update on November 12, 2025. Key clinical updates include completion of cohort 10 and initiation of an up-to-12 participant expansion cohort in the Phase 2 IST for preeclampsia (completion of the expansion expected in 1H 2026), screening to begin soon for a Part 3 fetal growth restriction cohort, and an in-person pre-IND meeting with the FDA for U.S. PE plans. Enrollment in the ReMEDy2 Phase 2/3 AIS trial is nearing 50% of the 200-patient interim-analysis target, expected in 2H 2026. Financials: $55.3M cash and short-term investments as of September 30, 2025, with anticipated runway into 2H 2027. Net loss was $24.0M for the nine months ended September 30, 2025.

DiaMedica Therapeutics (Nasdaq: DMAC) said President and CEO Rick Pauls will participate in the Jefferies Global Healthcare Conference in London on November 17-20, 2025.

Mr. Pauls will deliver a corporate presentation on Thursday, November 20, 2025, 10:00–10:25 AM GMT and will hold one-on-one investor meetings during the conference. DiaMedica is a clinical-stage biopharmaceutical company focused on treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, with lead candidate DM199, a recombinant KLK1 therapeutic.

DiaMedica Therapeutics (Nasdaq: DMAC) will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025.

The company will host a live conference call and business update on Thursday, November 13, 2025 at 8:00 AM ET (7:00 AM CT) with a simultaneous webcast available at https://app.webinar.net/MlAxZJky3Q7. Listeners are advised to log on or dial in 15 minutes early.

Replay options: telephonic replay available through November 20, 2025 (replay passcode 9449322) and webcast playback accessible on the investor relations events page for 12 months. DiaMedica is a clinical‑stage biopharmaceutical company focused on preeclampsia and acute ischemic stroke; its lead candidate DM199 is a recombinant form of KLK1 used in Asia for vascular indications.

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has granted stock options for 490,000 shares to five newly hired non-executive employees under its Amended and Restated 2021 Employment Inducement Incentive Plan.

The options have an exercise price of $6.76 per share, matching the company's closing price on September 18, 2025. The vesting schedule includes 25% after one year and the remaining 75% in quarterly installments over the following three years. The options have a ten-year term and were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, announced its participation in two upcoming investor conferences.

Management will attend the H.C. Wainwright Global Investment Conference from September 8-10, 2025, featuring a corporate presentation on September 9, and the Lake Street Capital Markets Best Ideas Growth Conference on September 11, 2025, for one-on-one meetings.

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, will participate in the Cantor Global Healthcare Conference in New York City.

CEO Rick Pauls and CBO Dave Wambeke will engage in a fireside chat on September 4, 2025, from 9:10-9:40 am ET at the New York Marriott Marquis. The session will be moderated by Joshua Schimmer, Managing Director at Cantor Fitzgerald. Management will also be available for one-on-one investor meetings during the conference.

DiaMedica Therapeutics (Nasdaq: DMAC) reported significant Q2 2025 developments and financial results. The company announced positive Phase 2 interim data for DM199 in preeclampsia, showing statistically significant reductions in blood pressure and no placental transfer. DiaMedica secured a $30.1 million private placement, extending its cash runway into H2 2027 with a proforma cash balance of $60 million.

Key financial metrics include R&D expenses of $5.8 million for Q2 2025 (up from $3.9M in Q2 2024) and a net loss of $7.7 million (increased from $5.1M). The company's ReMEDy2 Phase 2/3 trial for acute ischemic stroke continues with interim data expected in Q2 2026. Notable corporate developments include inclusion in the Russell 2000® and 3000® Indexes and appointment of Dr. Julie Krop as Chief Medical Officer.

DiaMedica Therapeutics (Nasdaq: DMAC) has appointed Dr. Julie Krop as its new Chief Medical Officer, effective immediately. Dr. Krop, who brings over 20 years of experience in strategic physician executive leadership, replaces Dr. Lorianne Masuoka, who resigned for personal reasons.

Dr. Krop joins from PureTech Health where she served as CMO and Head of Development. Her extensive experience includes leadership roles at Freeline Therapeutics, AMAG Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Notably, she has specific experience in preeclampsia drug development, which aligns with DiaMedica's focus on developing DM199 for preeclampsia and acute ischemic stroke treatments.

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will announce its second quarter 2025 financial results on August 12, 2025, after market close. The company will host a conference call on August 13, 2025, at 8:00 AM ET to discuss the results and provide a business update.

DiaMedica focuses on developing novel treatments for preeclampsia and acute ischemic stroke, with its lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic has established applications in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.